Arvinas chief accounting officer Loomis sells $13k in stock
#Arvinas #Insider Trading #Stock Sale #Financial Results #Parkinson's Disease #NASDAQ #Tax Obligations
📌 Key Takeaways
- Arvinas Chief Accounting Officer sold $13,473 worth of company stock to cover tax obligations
- Arvinas stock has surged 76% over the past six months, currently trading at $13.30
- Company reported disappointing Q4 2025 financial results with significant revenue and earnings shortfalls
- Wedbush raised price target to $11 while maintaining Neutral rating on the stock
📖 Full Retelling
Arvinas Chief Accounting Officer David K Loomis sold 1,108 shares of the company's common stock on February 23, 2026, for $12.16 per share, totaling approximately $13,473, to cover tax obligations through an automatically executed transaction by Arvinas, INC. Following the sale, Loomis directly owns 29,692 shares of Arvinas stock, which has surged 76% over the past six months and is currently trading at $13.30. Despite this positive stock performance, the biopharmaceutical company has faced significant financial challenges, reporting disappointing fourth quarter 2025 results with earnings per share at -$1.10, significantly missing forecasts of -$0.51, and revenue of $9.5 million, falling far below the anticipated $36.92 million. On a positive note, Wedbush raised its price target for Arvinas to $11 from $9 while maintaining a Neutral rating, citing pipeline progress, and the company's LRRK2 degrader ARV-102 for Parkinson's disease is on track with data presentation scheduled for March 2026, providing investors with crucial information about the company's ongoing projects and future prospects.
🏷️ Themes
Insider Trading, Financial Performance, Pharmaceutical Development
📚 Related People & Topics
Insider trading
Trading using nonpublic information
# Insider Trading **Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...
Nasdaq
American stock exchange
Nasdaq Stock Market (National Association of Securities Dealers Automated Quotations) is an American stock exchange, the second-largest by market cap on the list of stock exchanges, and the first fully electronic stock market. The exchange is based in Manhattan, New York City, and is among the most ...
Entity Intersection Graph
Connections for Insider trading:
🌐
SEC filing
5 shared
👤
New York Stock Exchange
4 shared
👤
Rachel Haurwitz
3 shared
🌐
ZWS
2 shared
🌐
Biopharmaceutical
2 shared
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Nasdaq ends more than 1% higher as Nvidia rises pre-earnings, tech extends rebound Nvidia’s results beat estimates, but Wall Street wants more cash return Gold prices head for fifth day of gains in six; JPMorgan sees more upside Nvidia set to report strong results and guidance, analysts say (South Africa Philippines Nigeria) Arvinas chief accounting officer Loomis sells $13k in stock By Investing.com Insider Trading Published 02/25/2026, 08:43 PM Arvinas chief accounting officer Loomis sells $13k in stock 0 ARVN 7.52% Arvinas (NASDAQ:ARVN) Chief Accounting Officer David K Loomis sold 1,108 shares of common stock on February 23, 2026, for $12.16, totaling approximately $13,473. The transaction was automatically executed by Arvinas , INC to cover tax obligations, and does not represent a discretionary trade. Following the transaction, Loomis directly owns 29,692 shares of Arvinas.The stock has surged 76% over the past six months, currently trading at $13.30. According to InvestingPro analysis, Arvinas appears undervalued at current levels, with subscribers accessing detailed Fair Value metrics and 5 additional ProTips for deeper investment insights. In other recent news, Arvinas Inc. reported disappointing financial results for the fourth quarter of 2025. The company’s earnings per share were -$1.10, significantly missing the forecasted -$0.51, resulting in a negative surprise of 115.69%. Additionally, revenue was reported at $9.5 million, which was well below the anticipated $36.92 million, marking a 74.27% shortfall. In another development, Wedbush has adjusted its price target for Arvinas, raising it to $11 from $9, while maintaining a Neutral rating on the stock. The firm cited the company’s pipeline progress and fourth-quarter financial results as factors in their decision. Data for the LRRK2 degrader ARV-102 in Parkinson’s disease patients is on track and will be presented at an upcoming international con...
Read full article at source